CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
2024 · Nature · 123 citations
https://doi.org/10.1038/s41586-024-07943-7
D
David Molkentine
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
163
Papers
1.3K
Citations
21
h-index
24
i10-index
David Molkentine is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer-related Molecular Pathways & Cancer Genomics and Diagnostics. The author has an h-index of 21, co-authored 139 publications.
ORCID: 0000-0003-0505-6815Papers by this author
worksInhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function
2021 · Nature Communications · 35 citations
https://doi.org/10.1038/s41467-021-26570-8
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
2010 · Investigational New Drugs · 27 citations
https://doi.org/10.1007/s10637-010-9389-3
Biological responses of human solid tumor cells to X‐ray irradiation within a 1.5‐Tesla magnetic field generated by a magnetic resonance imaging–linear accelerator
2016 · Bioelectromagnetics · 14 citations
https://doi.org/10.1002/bem.21991
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
2025 · Clinical Cancer Research · 14 citations
https://doi.org/10.1158/1078-0432.ccr-24-2310
Supp Figure 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
2024 · 0 citations
https://doi.org/10.1158/1078-0432.24947703.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat